This $9 billion investor is selling off Mesoblast shares. Should you?

Mesoblast was dealt a major blow last week when the FDA knocked back its flagship drug for a second time.

| More on:
A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mesoblast Ltd (ASX: MSB) shares took a cliff-fall last week after the United States Food and Drug Administration (FDA) once again knocked back its remestemcel-L drug.

And now it looks like one big institutional investor has lost at least some of its faith in the ASX biotech, selling millions of shares in the days since the bad news broke.

Which begs the question, should you do the same?

Mesoblast shares hit rock bottom

As shown in the chart, Mesoblast shares fell 57% last Friday when the company announced the bad news.

The share price fell from a close of $1.09 on Tuesday to 47 cents on Friday.

Mesoblast shares have continued to tumble in the fall-out, hitting an all-time low of 37.5 cents yesterday.

On Wednesday, Mesoblast shares opened at 38.5 cents, up 2.67%.

Big overseas investor sells down holdings

Two notices lodged with the ASX today reveal a large institutional investor has reduced its stake.

On the day of the news last Friday, M&G Plc (LON: MNG) — a global investment management firm with a $9 billion market capitalisation — offloaded 18.68 million of its 76,996,783 Mesoblast shares.

This reduced its stake in the company from 9.46% to 7.16%.

It remains a substantial investor, which is defined by a holding of 5%-plus.

On Monday this week, subsidiary company M&G Investments Funds also sold 10.39 million of its 51,954,410 Mesoblast shares, reducing its stake from 6.38% to 5.1%.

What's next for Mesoblast shares?

Doldrums, pretty much.

Investors are back in a holding pattern as Mesoblast begins preparations for the next study.

Just to recap, remestemcel-L is a stem-cell injectable medicine that treats steroid-refractory acute graft-versus-host disease (SR-aGVHD).

This is a severe immune reaction that can occur after bone marrow transplantation. It has a mortality rate of up to 90% in children.

Mesoblast's focus to date has been paediatric SR-aGVHD. There are currently no FDA-approved treatments in the US for children under 12 years of age with SR-aGVHD.

The next study Mesoblast will conduct will involve high-risk adults.

Last time the FDA knocked back remestemcel-L, it asked for another study in either kids or adults, and Mesoblast chose kids.

This time, Meosblast will do an adult study and has said this is in line with its commercial strategy anyway. The long-term plan has been to begin treating kids and then move to adults.

The next step will involve Mesoblast meeting with the FDA to design the study at what's called a Type A meeting within the next five weeks.

What should you do?

This is a very personal decision for Mesoblast shares investors.

Your choice partly depends on how patient you are.

The timeline last time involved almost three years.

Mesoblast received the first FDA knock-back in October 2020. It did more testing, then re-applied for approval in March this year, and the FDA made its decision this month.

So, that's almost three years.

Mesoblast has not provided an indicative timeline for the next study as yet.

Meantime, broker Bell Potter has reviewed the FDA's decision and downgraded Mesoblast shares to a speculative hold rating from a buy rating.

It has reduced its 12-month price target from $2 to 60 cents.

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »